Pemafibrate PPARα Modulation for Hypertriglyceridemia in Renal Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for moderate and severe hypertriglyceridemia, particularly in patients with renal impairment, are limited by the restrictions on existing PPARα agonists, which are contraindicated or require careful administration in renal dysfunction and have interactions with statins, and there is a need for a more potent and specific agent to effectively manage triglyceride levels and associated cardiovascular risks.
Innovation Solution
Pemafibrate, a selective PPARα modulator, is administered at therapeutically effective doses ranging from 0.2 to 1.0 mg daily, either as a single dose or divided twice daily, to treat moderate and severe hypertriglyceridemia in patients with normal or impaired renal function, including those on statin therapy, to reduce triglycerides and enhance HDL-C levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PPARα agonists (fibrates) are used to treat hypertriglyceridemia, then triglyceride levels are reduced, but the drugs are contraindicated or require careful administration in patients with renal dysfunction
Solution Approach 1:
The patent changes the pharmacological parameters by using pemafibrate, which has different pharmacokinetic properties compared to traditional fibrates. Pemafibrate is not metabolized by CYP450 enzymes and is not excreted through the kidneys, fundamentally altering the drug's interaction with renal function while maintaining its PPARα agonist activity for triglyceride reduction.
Solution Approach 2:
The patent creates a new PPARα agonist (pemafibrate) that copies the beneficial triglyceride-lowering effect of traditional fibrates but avoids their renal excretion pathway. This allows the drug to replicate the therapeutic effect without the contraindications associated with conventional fibrates in renal impairment.
2Reliability
If fibrates are administered to patients with renal dysfunction, then triglyceride levels may be reduced, but drug interactions with statins occur and require careful administration
Solution Approach 1:
The patent extracts the PPARα agonist activity from the traditional fibrate class, creating pemafibrate which lacks the problematic drug interaction profile of conventional fibrates. By separating the beneficial effect (PPARα activation) from the harmful interactions (CYP450 metabolism and statin interactions), the patent enables safer use in patients on statin therapy.
3Reliability
If omega-3 fatty acids are increased to manage triglyceride levels, then TG levels decrease, but adequate management is not achieved in severe HTG
Solution Approach 1:
The patent changes the mechanism of action from dietary supplementation (omega-3 fatty acids) to pharmacological activation of PPARα. This parameter change enables significantly more potent triglyceride reduction, achieving adequate management even in severe hypertriglyceridemia where dietary modifications alone are insufficient.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Pemafibrate demonstrates significant reductions in triglycerides and increases in HDL-C, along with favorable changes in lipid profiles, including Apo A1, Apo C3, and LDL particle conversion, effectively managing hypertriglyceridemia and reducing cardiovascular risk without significant drug interactions or renal pharmacokinetic changes, even in severe renal impairment.
Implementation Method 1
Fibrates improve TG and high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receiver alpha (PPARα)
Data Source
AI summary
The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.